title: Dyslipidemia intervention in metabolic syndrome: emphasis on improving lipids and clinical event reduction.
abstract: The metabolic syndrome is a common disorder characterized by central (especially intra-abdominal) obesity, hypertension, impaired glucose tolerance and atherogenic dyslipidemia (including the combination of hypertriglyceridemia and low levels of high-density lipoprotein cholesterol). In this article, the authors review interventions to improve this lipid profile and potentially reduce the risk of major cardiovascular events in patients with metabolic syndrome.
authors.affiliation: Department of Cardiovascular Diseases, John Ochsner Heart and Vascular Institute, Ochsner Clinical School, the University of Queensland School of Medicine, New Orleans, Louisiana 70121, USA. clavie@ochsner.org
authors.forename: Carl J
authors.initials: CJ
authors.lastname: Lavie
authors.forename: Richard V
authors.initials: RV
authors.lastname: Milani
authors.forename: James H
authors.initials: JH
authors.lastname: O'Keefe
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D024821:Metabolic Syndrome / Q000150:complications*; D012307:Risk Factors
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids